Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham R Foster

Showing results (161-170 of 191) with videos related to

Pageof 20
Sort By:
Journal of Hepatology|March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosisMassimo Puoti, Graham R Foster, Stanley Wang, et al.
Scientific Reports|May 6, 2016
Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis BHai Li, Liu-Ying Chen, Nan-Nan Zhang, et al.
Gut|August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
The International Journal on Drug Policy|June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyJason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Nature Genetics|April 11, 2017
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virusM Azim Ansari, Vincent Pedergnana, Camilla L C Ip, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Addiction (Abingdon, England)|January 30, 2019
The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in EnglandGraham I Harrison, Karen Murray, Roxanne Gore, et al.
Journal of Hepatology|January 7, 2015
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infectionPeter Ferenci, Tarik Asselah, Graham R Foster, et al.
BMC Infectious Diseases|November 26, 2025
Risk prediction models for targeted testing of HIV, hepatitis B and hepatitis C: a systematic review and meta-analysisWerner Leber, Hamzah Z Farooq, Jasmina Panovska-Griffiths, et al.
Pageof 20

Showing results (161-170 of 191) with videos related to

Sort By:
Pageof 20
Journal of Hepatology|March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosisMassimo Puoti, Graham R Foster, Stanley Wang, et al.
Scientific Reports|May 6, 2016
Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis BHai Li, Liu-Ying Chen, Nan-Nan Zhang, et al.
Gut|August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
The International Journal on Drug Policy|June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyJason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Nature Genetics|April 11, 2017
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virusM Azim Ansari, Vincent Pedergnana, Camilla L C Ip, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Addiction (Abingdon, England)|January 30, 2019
The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in EnglandGraham I Harrison, Karen Murray, Roxanne Gore, et al.
Journal of Hepatology|January 7, 2015
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infectionPeter Ferenci, Tarik Asselah, Graham R Foster, et al.
BMC Infectious Diseases|November 26, 2025
Risk prediction models for targeted testing of HIV, hepatitis B and hepatitis C: a systematic review and meta-analysisWerner Leber, Hamzah Z Farooq, Jasmina Panovska-Griffiths, et al.
Pageof 20